John Apeler Keller
Director/Board Member bij ViiV Healthcare Ltd.
Profiel
John Apeler Keller is currently a Director at ViiV Healthcare Ltd.
and a Director at Shionogi Ltd.
He was previously the President, CEO & Director at Shionogi, Inc. from 2010 to 2012.
Prior to that, he was a Director at diaDexus, Inc. from 2003 to 2010 and the Chief Business Officer & Executive Vice President at Incyte Corp.
from 2003 to 2008.
He was also a Partner at GSK Equity Investments Ltd.
from 2008 to 2010.
Keller held Vice President-Business Development positions at GSK Plc and Smithkline Beckman Corp.
Keller holds a doctorate from Rutgers State University of New Jersey and an undergraduate degree from The Johns Hopkins University.
Actieve functies van John Apeler Keller
| Bedrijven | Functie | Begin |
|---|---|---|
ViiV Healthcare Ltd.
 ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Director/Board Member | 31-10-2012 |
Shionogi Ltd.
 Shionogi Ltd. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi Ltd. is a British company that manufactures and distributes pharmaceutical products. The private company is based in London, UK. | Director/Board Member | 14-05-2014 |
Eerdere bekende functies van John Apeler Keller
| Bedrijven | Functie | Einde |
|---|---|---|
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Director/Board Member | 01-11-2010 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Private Equity Investor | 30-03-2010 |
| INCYTE CORPORATION | Corporate Officer/Principal | 12-09-2008 |
| GSK PLC | Corporate Officer/Principal | - |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Chief Executive Officer | - |
Opleiding van John Apeler Keller
| Rutgers State University of New Jersey | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Smithkline Beckman Corp
 Smithkline Beckman Corp Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beckman Corp is a private company that manufactures pharmaceutical products. The company is based in Philadelphia, PA. Smithkline Beckman was acquired by Smithkline Beecham Plc on July 27, 1989 for $16,082.37 million. | Health Technology |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Shionogi Ltd.
Shionogi Ltd. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi Ltd. is a British company that manufactures and distributes pharmaceutical products. The private company is based in London, UK. | Health Technology |
